Page last updated: 2024-12-06
actinoquinol
Description
Actinoquinol is a natural product with a quinone structure. It exhibits potent anti-inflammatory and antioxidant activity. Actinoquinol has been isolated from various microbial sources, including Streptomyces species. The compound has been shown to inhibit the production of pro-inflammatory cytokines, such as TNF-α and IL-6, and to protect cells from oxidative stress. It has also been found to have antimicrobial activity against certain bacteria. Actinoquinol is currently being investigated as a potential therapeutic agent for inflammatory diseases, such as arthritis and inflammatory bowel disease, and for neurodegenerative disorders. It is also being studied as a potential drug for treating infections.'
actinoquinol: radiation protectant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 23674 |
| CHEMBL ID | 1356732 |
| CHEBI ID | 135031 |
| SCHEMBL ID | 555260 |
| MeSH ID | M0555721 |
Synonyms (34)
| Synonym |
|---|
| nsc-165584 |
| 8-ethoxy-5-quinolinesulfonic acid |
| nsc165584 |
| actinoquinol |
| 5-quinolinesulfonic acid, 8-ethoxy- |
| 15301-40-3 |
| NCGC00166018-01 |
| CHEBI:135031 |
| 8-ethoxyquinoline-5-sulfonic acid |
| E0339 |
| actinochinolum |
| actinoquinolum |
| unii-470vqe23o3 |
| 8-ethoxy-5-chinolinsulfonsaeure |
| actinoquinolum [inn-latin] |
| einecs 239-334-9 |
| 470vqe23o3 , |
| nsc 165584 |
| actinoquinol [inn] |
| tox21_112289 |
| cas-15301-40-3 |
| dtxsid4046521 , |
| dtxcid2026521 |
| AKOS024319094 |
| FT-0637212 |
| CHEMBL1356732 |
| SCHEMBL555260 |
| actinoquinol [who-dd] |
| actinoquinol [mi] |
| mfcd00065059 |
| AS-61395 |
| Q15633953 |
| D90489 |
| STARBLD0009277 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Drug Classes (1)
| Class | Description |
|---|
| quinolines | A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (3)
Potency Measurements
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
| Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 30.07
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 30.07 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.51 (4.65) | | Search Engine Demand Index | 48.16 (26.88) | | Search Engine Supply Index | 3.05 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |